ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$163.7M
- Net margin
- —
Little or no net debt.
- Total debt
- $351K
- Cash
- $154.7M
- Debt / equity
- 0.00
Comfortably covers what is due within a year.
- Current assets
- $394.2M
- Current liabilities
- $27.8M
- Current ratio
- 14.16
Consumes cash and must keep raising it.
- Operating cash flow
- -$147.9M
- Free cash flow
- -$147.9M
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 47.6M
- Share growth (1y)
- 36.0%
- Cash runway
- 13 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
AVBP Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 10.35 M | 8.49 M | 6.65 M | 6.15 M | 5.90 M | 5.48 M |
| R&D Expense | 42.34 M | 37.62 M | 32.17 M | 32.17 M | 27.72 M | 61.29 M |
| Operating Expenses | 52.69 M | 46.11 M | 38.82 M | 38.32 M | 33.62 M | 66.77 M |
| Operating Income | -52.69 M | -46.11 M | -38.82 M | -38.32 M | -33.62 M | -66.77 M |
| Pretax Income | -49.89 M | -43.32 M | -35.54 M | -34.98 M | -31.40 M | -64.39 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -49.89 M | -43.32 M | -35.54 M | -34.98 M | -31.40 M | -64.39 M |
| EPS (Basic) | -1.05 | -0.96 | -0.84 | -0.83 | -0.90 | -1.90 |
| EPS (Diluted) | -1.05 | -0.96 | -0.84 | -0.83 | -0.90 | -1.90 |
| Shares Outstanding | 47.61 M | 45.07 M | 38.46 M | 41.91 M | 35.01 M | 33.90 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.